Phase 3 study: The efficacy of monovalent SARS-CoV-2 vaccine with AS03 adjuvant in adults

The effectiveness of a novel monovalent recombinant protein vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Cue Biopharma prioritizes autoimmune pipeline, axes a quarter of staff to save cash

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 27, 2024

Ascendis aims to raise $300M; Basilea inks up to $268M deal with BARDA

Plus, news about GSK, Novo Nordisk, Tanai Therapeutics, Nomic Bio, Brenus Pharma, Xspray, Achilles Therapeutics, BioXcel Therapeutics and Nuvalent: Ascendis’ $300M offering: The Danish company

September 20, 2024

SYNLAB AG: Cinven announces public delisting acquisition offer

SYNLAB AG / Key word(s): Delisting SYNLAB AG: Cinven announces public delisting acquisition offer | Conclusion of Delisting Agreement 31-May-2024 / 08:40 CET/CEST Disclosure of

June 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.